TABLE 1.
The characteristics of included trials.
| First author | Type of COVID-19 | Sample size (M/F) | Age (yrs) | Intervention | Control | Duration | Outcome measures |
|---|---|---|---|---|---|---|---|
| Ai et al. (2020) | Nonsevere | T:55 (24/31) C:43 (17/26) | T:57.4 ± 21.3 C:50.8 ± 23.5 | Pneumonia No.1 formula (1 dose/d) + conventional therapy | Conventional therapy including arbidol, lopinavir/tonavir, chloroquine, and symptomatic treatment | 12 days | Clinical cure rate, inflammatory biomarkers, and adverse events |
| Ding et al. (2020) | Mild/moderate/severe | T:51 (39/12) C:49 (39/10) | T:57.4 ± 21.3 C:50.8 ± 23.5 | Qingfei Touxie Fuzheng recipe (1 dose/d) + conventional therapy | Conventional therapy including interferon-α, ribavirin, quinolones and/or third-generation cephalosporins, and symptomatic treatment | 10 days | Lung CT, clinical symptoms, inflammatory biomarkers, and adverse events |
| Duan et al. (2020) | Mild | T:82 (39/43) C:41 (23/18) | T:51.99 ± 13.88 C:50.29 ± 13.17 | Jinhua Qinggan granule (1 dose/time, tid) + conventional therapy | Conventional therapy including antiviral, anti-infection, and other symptomatic treatments | 5 days | Clinical symptoms and adverse events |
| Fu et al. (2020a) | Mild/moderate | T:32 (17/15) C:33 (19/14) | T:43.26 ± 7.15 C:43.68 ± 6.45 | Toujie Quwen granule (1 dose/time, bid) + conventional therapy | Conventional therapy including abidor tablets, moxifloxacin tablets, and ambroxol tablets | 10 days | Lung CT, clinical cure rate, rate of conversion to severe cases, clinical symptoms, inflammatory biomarkers, and adverse events |
| Fu et al. (2020b) | Moderate | T:37 (19/18) C:36 (19/17) | T:45.26 ± 7.25 C:44.68 ± 7.45 | Toujie Quwen granule (1 dose/time, bid) + conventional therapy | Conventional therapy including abidor tablets and ambroxol tablets | 15 days | Clinical cure rate, rate of conversion to severe cases, clinical symptoms, inflammatory biomarkers, and adverse events |
| Hu et al. (2020) | Moderate | T:100 (49/51) C:100 (55/45) | T:47.00 ± 14.06 C:49.28 ± 11.14 | Jinyinhua oral liquid (120 ml/time, tid) + conventional therapy | Conventional therapy including interferon-α, lopinavir/tonavir tablets, and symptomatic treatment | 10 days | Lung CT, virus nucleic acid testing, rate of conversion to severe cases, and adverse events |
| Hu et al. (2020) | Mild/moderate | T:142 (79/63) C:142 (71/71) | T:50.4 ± 15.2 C:51.8 ± 14.8 | Lianhua Qingwen capsule (6 g, tid) + conventional therapy | Conventional therapy including oxygen therapy, antiviral medications, and symptomatic therapies | 14 days | Lung CT, clinical cure rate, virus nucleic acid testing, rate of conversion to severe cases, clinical symptoms, and adverse events |
| Yu et al. (2020) | Mild/moderate | T:147 (82/65) C:148 (89/59) | T:48.27 ± 9.56 C:47.25 ± 8.67 | Lianhua Qingwen granule (6 g, tid) + conventional therapy | Conventional therapy including abidor tablets, moxifloxacin tablets, and ambroxol tablets | 7 days | Lung CT, clinical cure rate, rate of conversion to severe cases, clinical symptoms inflammatory biomarkers, and adverse events |
| Zhang et al. (2020) | Moderate | T:80 (50/30) C:40 (23/17) | T:53.4 ± 13.70 C:52.0 ± 14.10 | Jinyinhua oral liquid (60 ml/time, tid) + conventional therapy | Conventional therapy including interferon-α, lopinavir, tonavir tablets, and symptomatic treatment | 10 days | Rate of conversion to severe cases, clinical symptoms, and adverse events |